Related Experiment Video

Updated: Jul 24, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

Association between statin therapy and mortality in patients on dialysis after atherosclerotic cardiovascular

Myunhee Lee1,2, Won Jung Choi3, Yunhee Lee4

  • 1Division of Cardiology, Department of Internal Medicine, Daejeon St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.

Scientific Reports
|July 6, 2023
PubMed

Insights

Statin therapy for atherosclerotic cardiovascular disease (ASCVD) patients on dialysis significantly lowers long-term mortality risk. This study found statins reduced all-cause mortality in dialysis patients post-ASCVD event.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Statin therapy is crucial for secondary prevention in atherosclerotic cardiovascular disease (ASCVD).
  • The efficacy of statins in patients undergoing chronic dialysis is not well-established.
  • Atherosclerotic cardiovascular disease is a leading cause of mortality in patients with chronic kidney disease.

Purpose of the Study:

  • To investigate the impact of statin therapy on long-term mortality in patients on dialysis following a first-time ASCVD event.
  • To assess the association between statin use and all-cause mortality in this specific patient population.

Main Methods:

  • Utilized the Korean National Health Insurance Service database for patient data.
  • Included patients aged 18 years or older on maintenance dialysis with a first-time ASCVD event between 2013 and 2018.
  • Employed Cox proportional hazards regression models, adjusting for demographic factors and comorbidities, to analyze the association between statin use and mortality.

Main Results:

  • Over 17,000 dialysis patients were analyzed; 55.7% received statin therapy post-ASCVD event.
  • Statin use was associated with a significantly lower risk of all-cause mortality (HR: 0.92; 95% CI: 0.88-0.97).
  • Moderate-intensity statins were the most common type used among statin recipients.

Conclusions:

  • Statin therapy demonstrated a significant reduction in long-term all-cause mortality for patients on dialysis after an ASCVD event.
  • Despite limited prior evidence, statins are widely prescribed in this population.
  • These findings support the use of statins for secondary prevention in dialysis patients with ASCVD.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.4K
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.6K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
702
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
13
Dialysis01:27

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
372
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
23
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
45
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
10